Emera (TSE:EMA – Get Free Report) had its target price increased by CIBC from C$63.00 to C$64.00 in a research report issued on Thursday,BayStreet.CA reports. The firm presently has an “outperform” rating on the stock. CIBC’s price target indicates a potential upside of 4.22% from the company’s current price.
A number of other brokerages have also recently weighed in on EMA. Royal Bank of Canada raised their price objective on shares of Emera from C$60.00 to C$63.00 in a research note on Monday, February 24th. Scotiabank lifted their price objective on Emera from C$60.00 to C$62.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. UBS Group raised their price target on shares of Emera from C$54.00 to C$59.00 in a research note on Friday, March 21st. Raymond James reduced their price objective on shares of Emera from C$64.00 to C$59.00 and set an “outperform” rating on the stock in a research note on Thursday, April 17th. Finally, BMO Capital Markets boosted their price target on Emera from C$58.00 to C$60.00 in a report on Monday, February 24th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Emera has an average rating of “Moderate Buy” and a consensus price target of C$58.64.
Get Our Latest Stock Report on Emera
Emera Trading Up 0.4 %
Emera Company Profile
Emera Incorporated, through its subsidiaries, engages in the generation, transmission, and distribution of electricity to various customers. The company operates through Florida Electric Utility, Canadian Electric Utilities, Other Electric Utilities, Gas Utilities and Infrastructure, and Other segments.
Featured Articles
- Five stocks we like better than Emera
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Short Sellers Gave Up on These 3 Names Recently
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- 3 Boring Stocks Outperforming the Market This Year
- What Are Dividend Contenders? Investing in Dividend Contenders
- If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
Receive News & Ratings for Emera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emera and related companies with MarketBeat.com's FREE daily email newsletter.